CA2945573A1 - Crispr systems for antibiotic-resistant microorganisms - Google Patents

Crispr systems for antibiotic-resistant microorganisms Download PDF

Info

Publication number
CA2945573A1
CA2945573A1 CA2945573A CA2945573A CA2945573A1 CA 2945573 A1 CA2945573 A1 CA 2945573A1 CA 2945573 A CA2945573 A CA 2945573A CA 2945573 A CA2945573 A CA 2945573A CA 2945573 A1 CA2945573 A1 CA 2945573A1
Authority
CA
Canada
Prior art keywords
sequence
dna
spacer
antibiotic
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2945573A
Other languages
English (en)
French (fr)
Inventor
Yoshikazu Mikawa
Conrad Lichtenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nemesis Bioscience Ltd
Original Assignee
Nemesis Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53008804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2945573(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1406674.0A external-priority patent/GB201406674D0/en
Priority claimed from GB201413719A external-priority patent/GB201413719D0/en
Priority claimed from GB201418508A external-priority patent/GB201418508D0/en
Application filed by Nemesis Bioscience Ltd filed Critical Nemesis Bioscience Ltd
Publication of CA2945573A1 publication Critical patent/CA2945573A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2945573A 2014-04-14 2015-04-14 Crispr systems for antibiotic-resistant microorganisms Pending CA2945573A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1406674.0 2014-04-14
GBGB1406674.0A GB201406674D0 (en) 2014-04-14 2014-04-14 Therapeutic
GB1413719.4 2014-08-01
GB201413719A GB201413719D0 (en) 2014-08-01 2014-08-01 Therapeutic
GB201418508A GB201418508D0 (en) 2014-10-17 2014-10-17 Therapeutic
GB1418508.6 2014-10-17
PCT/GB2015/051132 WO2015159068A1 (en) 2014-04-14 2015-04-14 Therapeutic

Publications (1)

Publication Number Publication Date
CA2945573A1 true CA2945573A1 (en) 2015-10-22

Family

ID=53008804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2945573A Pending CA2945573A1 (en) 2014-04-14 2015-04-14 Crispr systems for antibiotic-resistant microorganisms

Country Status (13)

Country Link
US (2) US20170037414A1 (https=)
EP (2) EP3132034B1 (https=)
JP (2) JP6849435B2 (https=)
CN (1) CN106536739B (https=)
AU (2) AU2015248621B2 (https=)
CA (1) CA2945573A1 (https=)
DK (1) DK3132034T3 (https=)
ES (1) ES2827279T3 (https=)
HU (1) HUE051354T2 (https=)
PL (1) PL3132034T3 (https=)
PT (1) PT3132034T (https=)
SI (1) SI3132034T1 (https=)
WO (1) WO2015159068A1 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
JP2017512481A (ja) 2014-04-08 2017-05-25 ノースカロライナ ステート ユニバーシティーＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｃｒｉｓｐｒ関連遺伝子を用いた、ｒｎａ依存性の転写抑制のための方法および組成物
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP3186375A4 (en) 2014-08-28 2019-03-13 North Carolina State University Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING
EP3711488A1 (en) 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
EA201792663A1 (ru) 2015-05-29 2018-04-30 Норт Каролина Стейт Юниверсити Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
WO2016205276A1 (en) 2015-06-15 2016-12-22 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
EP3356533A1 (en) 2015-09-28 2018-08-08 North Carolina State University Methods and compositions for sequence specific antimicrobials
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
CN105463003A (zh) * 2015-12-11 2016-04-06 扬州大学 一种消除卡那霉素耐药基因活性的重组载体及其构建方法
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017197206A1 (en) * 2016-05-11 2017-11-16 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for altering bacterial fitness
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11345924B2 (en) * 2017-05-11 2022-05-31 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Creation of herbicide resistant gene and use thereof
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CN111052248B (zh) * 2017-09-05 2024-04-02 自适应噬菌体治疗公司 细菌菌株对治疗组合物的敏感性谱的确定方法
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CA3099316A1 (en) * 2018-05-04 2019-11-07 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
JP6923862B2 (ja) * 2018-05-22 2021-08-25 学校法人自治医科大学 抗菌ファージ、治療用組成物、殺菌剤、食品、細菌判別キット、治療用組成物製造方法、細菌除去方法、細菌判別方法、及び動物治療方法
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
WO2019227080A1 (en) * 2018-05-25 2019-11-28 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3851528A4 (en) * 2018-09-12 2023-12-06 Institute for Basic Science COMPOSITION FOR INDUCATING DEATH OF CELLS HAVING MUTATED GENE AND METHOD FOR INDUCATING DEATH OF CELLS HAVING MODIFIED GENE USING THE COMPOSITION
WO2020072254A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for killing target cells
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
WO2020072248A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
CN111378660B (zh) * 2020-02-29 2021-08-06 浙江大学 一种靶向四环素抗性基因tetA的sgRNA及其敲除载体、载体构建方法和应用
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
WO2021231689A1 (en) * 2020-05-14 2021-11-18 Chan Zuckerberg Biohub, Inc. Phage-mediated delivery of genes to gut microbiome
CA3187281A1 (en) * 2020-06-15 2021-12-23 Laboratory Corporation Of America Holdings Methods for the diagnosis and treatment of biofilm-related infections
CN114540389B (zh) * 2020-11-26 2024-05-14 深圳华大生命科学研究院 一种制备基因工程病毒的方法及其应用
US12421561B2 (en) * 2021-02-11 2025-09-23 Brigham Young University Composition, method, and system for a rapid, real-time pentaplex PCR assay for major beta-lactamase genes
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN118421634A (zh) * 2024-07-02 2024-08-02 广州明迅生物科技有限责任公司 一种用于切割基因的sgRNA序列、表达载体、及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2341149T3 (en) * 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
WO2010075424A2 (en) * 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
EP2840140B2 (en) * 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
EP4074330A1 (en) * 2013-09-05 2022-10-19 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
US9322037B2 (en) * 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN106459995B (zh) * 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物

Also Published As

Publication number Publication date
JP2017513489A (ja) 2017-06-01
PT3132034T (pt) 2020-11-12
CN106536739B (zh) 2021-08-03
AU2015248621A1 (en) 2016-11-17
DK3132034T3 (da) 2020-10-19
EP3132034A1 (en) 2017-02-22
ES2827279T3 (es) 2021-05-20
US20180362990A1 (en) 2018-12-20
US20170037414A1 (en) 2017-02-09
WO2015159068A1 (en) 2015-10-22
SI3132034T1 (sl) 2020-12-31
AU2015248621B2 (en) 2020-08-27
HUE051354T2 (hu) 2021-03-01
JP6849435B2 (ja) 2021-03-24
CN106536739A (zh) 2017-03-22
EP3132034B1 (en) 2020-08-19
PL3132034T3 (pl) 2021-04-06
AU2020277257A1 (en) 2021-01-07
EP3766971A1 (en) 2021-01-20
JP2021013383A (ja) 2021-02-12

Similar Documents

Publication Publication Date Title
AU2015248621B2 (en) Therapeutic
AU2016308591B2 (en) Delivery vehicle
CN107208070B (zh) 细菌基因的靶向消除
Arthur et al. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147
Grohmann et al. Conjugative plasmid transfer in gram-positive bacteria
EP3322797B1 (en) Improving sequence-specific antimicrobials by blocking dna repair
EP3630979A2 (en) Genetic systems that defend against foreign dna and uses thereof
US20190330643A1 (en) Engineering of bacteriophages by genome editing using the crispr-cas9 system
Dennis et al. Identification and characterization of the tolQRA genes of Pseudomonas aeruginosa
KR102876612B1 (ko) 하나 이상의 비-고유 꼬리 섬유를 가지는 비-복제성 형질도입 입자 및 형질도입 입자-기반 리포터 시스템
MXPA04002899A (es) Bacteriofagos deficientes en lisina, que tienen inmunogenicidad reducida.
KR20230156365A (ko) 메타게놈 유래의 새로운 CRISPR-Cas 뉴클레아제
US20050118719A1 (en) Nucleic acid delivery and expression
KR20140002463A (ko) 디포신 및 그의 사용 방법
WO2019152941A1 (en) Engineered gut microbes for reduction of reactivation of detoxified drugs
HK1234437B (en) Therapeutic
HK1234437A1 (en) Therapeutic
JP2023507163A (ja) バクテロイデスにおけるゲノム編集
EP0687299A1 (en) Bacteriophage lc3-based vector system for transformation of bacteria
KR20150127266A (ko) 디포신류 및 이들의 사용 방법
Bohaychuk Heterologous expression of brochocin-C in Carnobacterium spp.
Class et al. Patent application title: BACTERIOPHAGE FOR BIOCONTROL OF SALMONELLA AND IN THE MANUFACTURING OR PROCESSING OF FOODS Inventors: Martin Johannes Loessner (Ebmatingen, CH) Steven Hagens (Bennekom, NL) Albert Johannes Hendrikus Slijkhuis (Nijmegen, NL) Jochen Achim Klumpp (Gockhausen, CH) Roger Marti (Zurich, CH) Assignees: Micreos BV

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200407